Systemic sclerosis-associated fibrosis: An accelerated aging phenotype?

Current Opinion in Rheumatology

Volumn 27, Issue 6, 2015, Pages 571-576

  Luckhardt, Tracy R ^a   Thannickal, Victor J ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Aging; Fibrosis; Systemic sclerosis

Indexed keywords

BETA CATENIN; MITOCHONDRIAL DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SIRTUIN 1; WNT PROTEIN;

AUTOPHAGY; BIOACCUMULATION; CELL AGING; DISEASE ASSESSMENT; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA MODIFICATION; ENDOTHELIUM CELL; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; IMMUNE DYSREGULATION; IMMUNE SYSTEM; LUNG FIBROSIS; NONHUMAN; PATHOGENESIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; SENESCENCE; SYSTEMIC SCLEROSIS; AGING; FIBROBLAST; FIBROSIS; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY;

AGING; AUTOPHAGY; CELL AGING; EPIGENESIS, GENETIC; FIBROBLASTS; FIBROSIS; HUMANS; MITOCHONDRIAL DISEASES; PHENOTYPE; SCLERODERMA, SYSTEMIC;

EID: 84942511812     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000219     Document Type: Review

References (54)

1. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48:2246-2255.
2. Ho YY, Lagares D, Tager AM, Kapoor M. Fibrosis: a lethal component of systemic sclerosis. Nat Rev Rheumatol 2014; 10:390-402.
3. Furst DE, Fernandes AW, Iorga SR, et al. Epidemiology of systemic sclerosis in a large US managed care population. J Rheumatol 2012; 39:784-786.
4. Ferri C, Sebastiani M, Lo Monaco A, et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. Autoimmun Rev 2014; 13:1026-1034.
5. Strickland G, Pauling J, Cavill C, et al. Mortality in systemic sclerosis-a single centre study from the UK. Clin Rheumatol 2013; 32:1533-1539.
6. Manno RL, Wigley FM, Gelber AC, Hummers LK. Late-age onset systemic sclerosis. J Rheumatol 2011; 38:1317-1325.
7. Perez-Bocanegra C, Solans-Laque R, Simeon-Aznar CP, et al. Age-related survival and clinical features in systemic sclerosis patients older or younger than 65 at diagnosis. Rheumatology 2010; 49:1112-1117.
8. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
9. Vivero M, Padera RF. Histopathology of lung disease in the connective tissue diseases. Rheum Dis Clin North Am 2015; 41:197-211.
10. Herzog EL, Mathur A, Tager AM, et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014; 66:1967-1978.
11. Thannickal VJ. Mechanistic links between aging and lung fibrosis. Biogerontology 2013; 14:609-615.
12. Lopez-Otin C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell 2013; 153:1194-1217.
13. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell 2014; 159:709-713.
14. Cannizzo ES, Clement CC, Sahu R, et al. Oxidative stress, inflamm-aging and immunosenescence. J Proteomics 2011; 74:2313-2323.
15. Fulop T, Le Page A, Fortin C, et al. Cellular signaling in the aging immune system. Curr Opin Immunol 2014; 29:105-111.
16. Faner R, Rojas M, Macnee W, Agusti A. Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:306-313.
17. Thewissen M, Somers V, Venken K, et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin Immunol 2007; 123:209-218.
18. Rodriguez-Carrio J, Alperi-Lopez M, Lopez P, et al. TNFalpha polymorphismas marker of immunosenescence for rheumatoid arthritis patients. Exp Gerontol 2015; 61:123-129.
19. Gilani SR, Vuga LJ, Lindell KO, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One 2010; 5:e8959.
20. Ugarte-Gil MF, Sanchez-Zuniga C, Gamboa-Cardenas RV, et al. Circulating naive and memory CD4+ T-cells and metabolic syndrome in patients with systemic lupus erythematosus: data from a primarily Mestizo population. Rheumatology 2015; 54:1302-1307.
21. Pinto AR, Godwin JW, Chandran A, et al. Age-related changes in tissue macrophages precede cardiac functional impairment. Aging 2014; 6:399-413.
22. Brunet A, Berger SL. Epigenetics of aging and aging-related disease. J Gerontol A Biol Sci Med Sci 2014; 69 (Suppl 1):S17-S20.
23. Altorok N, Almeshal N, Wang Y, Kahaleh B. Epigenetics, the holy grail in the pathogenesis of systemic sclerosis. Rheumatology 2014. [Epub ahead of print]
24. Zerr P, Palumbo-Zerr K, Huang J, et al. Sirt1 regulates canonical TGF-beta signalling to control fibroblast activation and tissue fibrosis. Ann Rheum Dis 2014. [Epub ahead of print]
25. Wei J, Ghosh AK, Chu H, et al. The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor beta signaling. Arthritis Rheumatol 2015; 67:1323-1334.
26. Sampson N, Berger P, Zenzmaier C. Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic disease. Oxid Med Cell Longev 2012; 2012:458276.
27. Jiang F, Liu GS, Dusting GJ, Chan EC. NADPH oxidase-dependent redox signaling in TGF-beta-mediated fibrotic responses. Redox Biol 2014; 2:267-272.
28. Spadoni T, Svegliati Baroni S, Amico D, et al. A reactive oxygen speciesmediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol 2015; 67:1611-1622.
29. Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009; 15:1077-1081.
30. Hecker L, Logsdon NJ, Kurundkar D, et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med 2014; 6:231ra47.
31. Sanders YY, Liu H, Liu G, Thannickal VJ. Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence. Free Radic Biol Med 2015; 79:197-205.
32. Sanders YY, Hagood JS, Liu H, et al. Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice. Eur Respir J 2014; 43:1448-1458.
33. Dees C, Distler JH. Canonical Wnt signalling as a key regulator of fibrogenesis: implications for targeted therapies? Exp Dermatol 2013; 22:710-713.
34. Dees C, Schlottmann I, Funke R, et al. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis 2014; 73:1232-1239.
35. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013; 75:685-705.
36. Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134:657-667.
37. Munoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol 2014; 15:482-496.
38. Piera-Velazquez S, Jimenez SA. Role of cellular senescence and NOX4-mediated oxidative stress in systemic sclerosis pathogenesis. Curr Rheumatol Rep 2015; 17:473.
39. Bratic A, Larsson NG. The role of mitochondria in aging. J Clin Invest 2013; 123:951-957.
40. Thannickal VJ, Murthy M, Balch WE, et al. Blue journal conference. Aging and susceptibility to lung disease. Am J Respir Crit Care Med 2015; 191:261-269.
41. Lionaki E, Markaki M, Palikaras K, Tavernarakis N. Mitochondria autophagy and age-associated neurodegenerative diseases: new insights into a complex interplay. Biochim Biophys Acta 2015. [Epub ahead of print]
42. Bueno M, Lai YC, Romero Y, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest 2015; 125:521-538.
43. Patel AS, Song JW, Chu SG, et al. Epithelial cell mitochondrial dysfunction and PINK1 are induced by transforming growth factor-beta1 in pulmonary fibrosis. PLoS One 2015; 10:e0121246.
44. Gazdhar A, Lebrecht D, Roth M, et al. Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis. Sci Rep 2014; 4:5336.
45. Song X, Wang B, Lin S, et al. Astaxanthin inhibits apoptosis in alveolar epithelial cells type II in vivo and in vitro through the ROS-dependent mitochondrial signalling pathway. J Cell Mol Med 2014; 18:2198-2212.
46. Patel AS, Morse D, Choi AM. Regulation and functional significance of autophagy in respiratory cell biology and disease. Am J Respir Cell Mol Biol 2013; 48:1-9.
47. Madeo F, Zimmermann A, Maiuri MC, Kroemer G. Essential role for autophagy in life span extension. J Clin Invest 2015; 125:85-93.
48. Del Principe D, Vona R, Giordani L, et al. Defective autophagy in fibroblasts may contribute to fibrogenesis in autoimmune processes. Curr Pharm Des 2011; 17:3878-3887.
49. Margaritopoulos GA, Tsitoura E, Tzanakis N, et al. Self-eating: friend or foe? The emerging role of autophagy in idiopathic pulmonary fibrosis. Biomed Res Int 2013; 2013:420497.
50. Araya J, Kojima J, Takasaka N, et al. Insufficient autophagy in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2013; 304:L56-L69.
51. Cabrera S, Maciel M, Herrera I, et al. Essential role for the ATG4B protease and autophagy in bleomycin-induced pulmonary fibrosis. Autophagy 2015; 11:670-684.
52. Nho RS, Hergert P. IPF fibroblasts are desensitized to type I collagen matrixinduced cell death by suppressing low autophagy via aberrant Akt/mTOR kinases. PLoS One 2014; 9:e94616.
53. Frech T, De Domenico I, Murtaugh MA, et al. Autophagy is a key feature in the pathogenesis of systemic sclerosis. Rheumatol Int 2014; 34:435-439.
54. Dumit VI, Kuttner V, Kappler J, et al. Altered MCM protein levels and autophagic flux in aged and systemic sclerosis dermal fibroblasts. J Invest Dermatol 2014; 134:2321-2330.